Emerald Health Therapeutics Enters Research Agreement with VivaCell Biotechnologies to Evaluate Proprietary Cannabis Products...
October 03 2018 - 7:00AM
Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF)
(“Emerald”) has entered into a research agreement with VivaCell
Biotechnologies Spain S.L.U. (“VivaCell”). VivaCell is an institute
focused on cannabis research, which will provide its
cannabis-industry-leading contract research organization (CRO)
services to Emerald to elucidate the mechanism of action of
proprietary formulations and dosage forms that Emerald is
developing. This collaboration has the potential to strengthen
Emerald’s intellectual property portfolio and assist in
establishing Emerald as a leader in the development of proprietary
cannabis products for medical-use and improved adult-use products
with more precise and consistent delivery, dosage, and
formulations.
“There are a rare few organizations that focus
their understanding of the cannabis plant at the heart of its
scientific development and strategic operations. We’re fortunate to
have VivaCell as part of the Emerald Health group of companies and
look forward to working on this project,” said Chris Wagner, CEO of
Emerald. “With 17 patents filed to date, we are advancing our
product development process. The data from this work will aid us in
this process. Our goal is to expand our product pipeline with
innovative products substantiated by scientific data and protected
by our intellectual property.”
VivaCell was founded in 2003 as a spin-off of
the AINP and Cannabis EU projects by a group of
internationally renowned researchers. VivaCell’s
in-house research and development capabilities are
complemented through its partnerships with top academic research
centers at the University of Córdoba, Complutense University of
Madrid, Instituto Cajal in Madrid, and University of Piemonte
Orientale (Italy). This model allows VivaCell to utilize a wide
breadth of expertise in biomedicine, pharmacology and chemistry to
optimize their contract research offerings to support the
product development of their clients.
“Emerald’s focus on scientific innovation has
the potential to produce a future product pipeline of next-wave
cannabis products that fit the needs and preferences of both
adult-use consumers and patients,” said Mari-Luz Bellido, Managing
Director of VivaCell. “We believe that cannabis has the potential
to be developed into consistent, high-value downstream products. We
are pleased to support the development of Emerald’s intellectual
property by employing our deep cannabis research experience and
conduct rigorous preclinical studies. ”
VivaCell is a wholly-owned subsidiary of Emerald
Health Sciences, which also owns approximately 32% of the issued
and outstanding shares of Emerald Health Therapeutics, Inc.
Accordingly, both VivaCell and EHS are related parties of the
Company for purposes of National Instrument 61-01: Protection of
Minority Security Holders in Special Transactions. The transaction
is exempt from the valuation and minority approval requirements of
NI 61-101 pursuant to the exemptions in Sections 5.5(b) and
5.7(1)(a) of NI 61-101.
About VivaCell
Biotechnologies Spain S.L.U.
VivaCell Biotechnologies España SL is a
privately held research company focused on new non-psychotropic
cannabinoids for the treatment of inflammatory and
neurodegenerative diseases. It is a worldwide pioneer in the
discovery and research of cannabidiol and cannabigerol chemical
derivatives that improve the therapeutic properties of the natural
cannabinoids. Additionally, VivaCell’s expertise includes research
on hemp extracts (non-psychotropic cannabis varieties) such as
CDE-001 to improve inflammatory skin conditions as atopic
dermatitis. In addition, as a leading cannabis research institute,
VivaCell provides broad contract research services that maintain
exceptionally high standards for their scientific teams, and
state-of-the-art facilities, with a focus on expediting research
programs, drug discovery and lead candidate selection, and
preclinical development. More information about the company is
available here.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. (TSXV: EMH;
OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s
Access to Cannabis for Medical Purposes Regulations and produces
and sells dried cannabis and cannabis oil for medical purposes.
Emerald owns 50% of Pure Sunfarms, which is converting a licensed
existing 1.1 million square foot greenhouse in Delta, BC, and is in
commercial production. It owns Agro-Biotech, a Québec-based
licensed cannabis grower with a 75,000 square foot indoor facility
and has secured a long-term supply contract for approximately 500
acres of industrial hemp in 2018 and up to 1000 acres in 2019 to
2022, which provides low-cost cannabidiol (CBD) supply for the
company’s manufacturing needs.. Emerald’s team is highly
experienced in life sciences, product development, large-scale
agri-business, and marketing, and is focused on developing
value-added cannabis-based products with potential wellness and
medical benefits. Emerald is part of the Emerald Health group,
which is broadly focused on developing pharmaceutical, botanical,
and nutraceutical products that may provide wellness and medical
benefits by interacting with the human body’s endocannabinoid
system.
Please visit www.emeraldhealth.ca for more
information or contact:Rob Hill, Chief Financial Officer(800) 757
3536 Ext. #5
Ray Lagace, Investor Relations Manager(800) 757
3536 Ext. #5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is definedin the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include strengthening Emerald’s intellectual property portfolio;
establishing Emerald as a leader in development of proprietary
cannabis products; advancing Emerald’s product development process;
expanding Emerald’s product pipeline with innovative products
substantiated by scientific data and protected by intellectual
property; and development of cannabis into consistent, high-value
downstream products. .
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of scientific
research; regulatory changes; demand for products; efficacy of
products; as well as the risk factors described in the Company’s
annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jul 2023 to Jul 2024